Aware Super Pty Ltd as trustee of Aware Super purchased a new position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) during the first quarter, HoldingsChannel reports. The firm purchased 250,920 shares of the company’s stock, valued at approximately $29,661,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Wealthfront Advisers LLC raised its stake in Zoetis by 178.0% during the first quarter. Wealthfront Advisers LLC now owns 42,240 shares of the company’s stock worth $4,993,000 after buying an additional 27,046 shares during the last quarter. MASTERINVEST Kapitalanlage GmbH grew its position in Zoetis by 15.8% in the 1st quarter. MASTERINVEST Kapitalanlage GmbH now owns 7,590 shares of the company’s stock valued at $897,000 after purchasing an additional 1,038 shares during the period. Hudson Canyon Capital Management increased its position in shares of Zoetis by 4.0% during the first quarter. Hudson Canyon Capital Management now owns 15,393 shares of the company’s stock worth $1,820,000 after acquiring an additional 593 shares in the last quarter. Sanctuary Advisors LLC raised its stake in shares of Zoetis by 7.9% in the first quarter. Sanctuary Advisors LLC now owns 51,818 shares of the company’s stock worth $6,125,000 after purchasing an additional 3,809 shares during the last quarter. Finally, Sigma Planning Corp grew its holdings in Zoetis by 181.2% during the first quarter. Sigma Planning Corp now owns 9,563 shares of the company’s stock worth $1,130,000 after buying an additional 6,162 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Stock Up 3.3%
Zoetis stock opened at $77.02 on Friday. The firm has a 50 day moving average price of $77.46 and a 200-day moving average price of $106.24. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $160.48. The company has a market capitalization of $32.29 billion, a P/E ratio of 12.77, a P/E/G ratio of 1.16 and a beta of 0.75.
Zoetis Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.8%. Zoetis’s dividend payout ratio is 35.16%.
Insiders Place Their Bets
In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The stock was purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 11,650 shares of company stock worth $886,384 over the last quarter. 0.22% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the stock. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. TD Cowen dropped their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Citigroup reduced their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, HSBC cut their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $120.83.
Zoetis News Summary
Here are the key news stories impacting Zoetis this week:
- Positive Sentiment: Zoetis announced the acquisition of VitalRADS, which should deepen its diagnostics business and broaden its cloud-based, AI-assisted veterinary workflow tools. Zoetis Gains as VitalRADS Deal Boosts Diagnostics Narrative
- Positive Sentiment: Zoetis launched Lenivia in Canada and the EU, giving the company a new international treatment option for canine osteoarthritis pain and potentially supporting sales growth. Zoetis Launches Lenivia in Canada and the European Union
- Neutral Sentiment: Several law firms issued reminders about an upcoming July 27 lead-plaintiff deadline in the pending securities class action, keeping legal uncertainty in focus for investors. Zoetis Inc. Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- Negative Sentiment: The class-action headlines highlight allegations of securities fraud tied to the period from January 2025 through May 2026, which could weigh on sentiment until the case is resolved. Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act
Zoetis Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Articles
- Five stocks we like better than Zoetis
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
